Techniques for treating narrow angle glaucomaClinicians have a variety of tools and options at their disposal to treat narrow angle glaucoma. Sunita Radhakrishnan, MD, provided an overview of these possibilities.
Glaucoma surveillance essential for optimizing patient outcomesGlaucoma progression occurs slowly in the vast majority of patients, and most patients with glaucoma will not go blind from the disease. However, it is important to get early diagnosis, treatment when indicated, and develop a disease surveillance protocol.
Numerous issues underlie unexplainable glaucoma progressionWhen glaucoma is progressing despite good intraocular pressure control, clinicians should consider a variety of issues before advancing patients along the therapeutic ladder.
Evidence-based answers to lifestyle questions on glaucomaYvonne Ou, MD, reviewed the scientific evidence regarding the effects of various lifestyle practices on glaucoma and IOP.
MIGS making big difference in glaucoma managementMicroinvasive glaucoma surgery devices already have transformed the management of glaucoma and will have a bigger impact in the future considering the options in the investigational pipeline and the opportunities they present.
Value-Based Payment program presents potential ramificationsOphthalmologists need to prepare their practices for the Value-Based Payment (VBP) program for Medicare services. VBP is a strategy to promote quality and value of health care services, with providers being paid based on value-of-care-delivered rather than volume. Regardless of the perspectives, the fact remains that reimbursement can increase or decrease substantially with the VBP program.
7 common mistakes in managing uveitic glaucomaGlaucoma is a common complication of uveitis, occurring in about 20% of affected eyes and arising through several different mechanisms. Here are seven common mistakes clinicians make in evaluating and managing elevated IOP in eyes with uveitis.
New approaches and technologies offer hope in vision restorationNew agents and devices offer promise to control IOP and slow, perhaps even stop, the advancing vision loss that is common in glaucoma. Research and development to restore vision is starting to show significant results in preclinical models and early stage clinical trials.